A last factor to consider when aiming to understand how EDI3 may influence cancer-related endpoint is that in addition to its enzymatic glycerophosphodiesterase domain, EDI3 also contains a carbohydrate binding domain that remains largely unexplored, which we have shown in unpublished work to bind glycogen. Here, GPCPD1 is linked to cancer.